As gene therapy continues to revolutionize modern medicine, the need for robust, scalable tools to evaluate vector performance and immune responses has never been greater. One critical challenge in this field is the detection of neutralizing antibodies (NAbs) against adeno-associated virus (AAV) vectors, which can significantly impact the efficacy of gene delivery.
Svar Life Science addresses this challenge with its innovative iLite AAV Nab assay platform - a powerful solution designed to streamline and standardize NAb detection across various AAV serotypes, including both established wildtypes as well as recombinant versions.